Bidirectional relationship between diabetes and pancreatic cancer: from mechanistic investigation to clinical application
- 1Center for Pancreatic Cancer Research, South China University of Technology
- 2Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine
Abstract
A well-established bidirectional causal relationship connects type 2 diabetes mellitus (T2DM) and pancreatic ductal adenocarcinoma (PDAC). Long-standing T2DM elevates pancreatic cancer risk approximately 1.8–2.2-fold, whereas 30%–74% of PDAC patients develop new-onset diabetes (NOD) 2–36 months before tumor detection, which mostly corresponds to tumour-originated type 3c pancreatogenic diabetes (T3cDM). Notably, 25%–40% of such patients achieve spontaneous glycemic recovery after R0 curative resection, solidifying the causal nature of PDAC-induced hyperglycemia. Six interrelated molecular mechanisms mediate their reciprocal crosstalk: chronic metabolic abnormality mediated by hyperinsulinemia and AGE-RAGE signaling, sustained inflammatory and macrophage remodeling, KRAS-driven oncogenic and epigenetic modification, pancreatic stellate cell-derived desmoplasia, tumor exosome-mediated β-cell damage, and gut-pancreas microbiome dysbiosis. Specifically, PDAC-secreted exosomes loaded with adrenomedullin, peritumor fibrotic islet destruction and circulating S100A8 peptide collectively lead to insulin deficiency, making T3cDM biochemically distinguishable from insulin-resistant classic T2DM by reduced pancreatic polypeptide and endogenous insulin concentrations. Clinically, END-PAC scoring and emerging machine learning algorithms facilitate risk stratification for early PDAC screening among patients aged 50 years or older with NOD. Nonetheless, prominent challenges remain: conflicting clinical data on the anti-PDAC potential of metformin and GLP-1RAs, ethnic heterogeneity limiting the generalizability of current prediction models, and up to 88% T3cDM misdiagnosis owing to the absence of global unified diagnostic benchmarks. Future translational research will center on prospective validation of multi-omic biomarkers, formulation of standardized T3cDM diagnostic criteria, large-scale screening trials, and rational repurposing of antidiabetic agents for pancreatic cancer prevention and adjuvant therapy.
Related
- The Bidirectional Relationship Between Rheumatoid Arthritis and Periodontitis: Current Evidence and Clinical Implications
- Bidirectional Mendelian randomization analysis reveals the causal relationship between rheumatoid arthritis and acute sinusitis
- Bidirectional regulation of pancreatic stellate cell-mediated pancreatic fibrosis by prostaglandin subtypes: mechanisms and therapeutic implications
- The Bidirectional Relationship Between Tuberculosis and Type 2 Diabetes Mellitus: Pathogenesis, Treatment Challenges, and Prevention Strategies
- A Bidirectional Relationship Between Spontaneous Coronary Artery Dissection and Stress-Induced Cardiomyopathy in a Perimenopausal Woman: A Case Report.
BibTeX
@article{wu2026bidirectional,
title = {{Bidirectional relationship between diabetes and pancreatic cancer: from mechanistic investigation to clinical application}},
author = {Jiangmin Wu and Tingting Jiang and Xiaojia Li and Dacheng Xie and Keping Xie},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1995824},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1995824/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bidirectional relationship between diabetes and pancreatic cancer: from mechanistic investigation to clinical application
AU - Jiangmin Wu
AU - Tingting Jiang
AU - Xiaojia Li
AU - Dacheng Xie
AU - Keping Xie
PY - 2026
DA - 2026/10/22
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1995824
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1995824/full
AB - A well-established bidirectional causal relationship connects type 2 diabetes mellitus (T2DM) and pancreatic ductal adenocarcinoma (PDAC). Long-standing T2DM elevates pancreatic cancer risk approximately 1.8–2.2-fold, whereas 30%–74% of PDAC patients develop new-onset diabetes (NOD) 2–36 months before tumor detection, which mostly corresponds to tumour-originated type 3c pancreatogenic diabetes (T3cDM). Notably, 25%–40% of such patients achieve spontaneous glycemic recovery after R0 curative resection, solidifying the causal nature of PDAC-induced hyperglycemia. Six interrelated molecular mechanisms mediate their reciprocal crosstalk: chronic metabolic abnormality mediated by hyperinsulinemia and AGE-RAGE signaling, sustained inflammatory and macrophage remodeling, KRAS-driven oncogenic and epigenetic modification, pancreatic stellate cell-derived desmoplasia, tumor exosome-mediated β-cell damage, and gut-pancreas microbiome dysbiosis. Specifically, PDAC-secreted exosomes loaded with adrenomedullin, peritumor fibrotic islet destruction and circulating S100A8 peptide collectively lead to insulin deficiency, making T3cDM biochemically distinguishable from insulin-resistant classic T2DM by reduced pancreatic polypeptide and endogenous insulin concentrations. Clinically, END-PAC scoring and emerging machine learning algorithms facilitate risk stratification for early PDAC screening among patients aged 50 years or older with NOD. Nonetheless, prominent challenges remain: conflicting clinical data on the anti-PDAC potential of metformin and GLP-1RAs, ethnic heterogeneity limiting the generalizability of current prediction models, and up to 88% T3cDM misdiagnosis owing to the absence of global unified diagnostic benchmarks. Future translational research will center on prospective validation of multi-omic biomarkers, formulation of standardized T3cDM diagnostic criteria, large-scale screening trials, and rational repurposing of antidiabetic agents for pancreatic cancer prevention and adjuvant therapy.
SN - 1664-2392
ER -